Want to see BLGO full AI Analyst Report?
BioLargo (BLGO) AI Stock Analysis
BioLargo
(Other OTC:BLGO)
The overall score is extremely low, driven primarily by a dire financial position with negative equity, steep operating losses, and high cash burn. Technicals confirm a stock in freefall, trading at a fraction of its moving averages. While the earnings call outlines potential future catalysts from new ventures, these are early-stage and unproven, failing to offset the immediate and severe financial distress. The company's survival hinges on successful execution of speculative projects and securing non-dilutive financing.
BioLargo (BLGO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $23.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 409.55K
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- -0.08
- Revenue Growth
- -70.95%
- EPS Growth
- -257.36%
- Country
- US
- Employees
- 45
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
BioLargo Business Overview & Revenue Model
Company Description
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination...
How the Company Makes Money
BioLargo generates revenue primarily through a combination of (1) product and technology commercialization and (2) service/engineering activities tied to environmental solutions. Product-driven revenue can include sales of odor/VOC control products a...
BioLargo Earnings Call Summary
The call was strongly forward-looking and optimistic, emphasizing revenue growth in the core engineering business, multiple distribution channels for Clyra, PFAS commercial progress, new ventures, and potential contract opportunities. However, management also acknowledged a difficult year marked by a market capitalization decline of more than 60%, the loss of the Pooph business, a close to $4 million write-down, Clyra’s launch delay and burn rate, and ongoing financing and regulatory uncertainty. The number and strength of the stated achievements and initiatives outweighed the stated challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects to launch the consumer products category in the October time frame, with a conservative target of about half the numbers that Pooph generated, realistically coming in the $15-plus million range over the first course of a year to 1.5 years; Clyra’s national distribution launch is targeted for 2027 start, with a 3- to 6-month setup, while its 3 active distributors encompass probably 70-plus percent of the market. Cellinity’s strategy involves factories with about $250 million of CapEx, factories of about $170 million each, incentives as much as 50% of CapEx, and a Puerto Rico project where 80-plus percent of the project can get financed with incentives; its design targets 10 years, no degradation and another 10-year cycle with only 4% degradation, versus a 7-year market with up to 15% degradation. The minerals facility is expected to move to Phase 2, probably somewhere around the $10 million range, take about a year, 1.5 years, and potentially lead to a design build probably something in the $40 million range; water projects being scoped include $5 million, $10 million, $25 million and $30 million projects, including systems of 3 million gallons a day, with a proposed 80% reduction in OpEx. A multimillion-dollar military grant is hoped to get funded in Q1, and the annual meeting target is December 1.
BioLargo Financial Statement Overview
Summary
Financial performance is critically weak. TTM revenue declined 27% YoY, operating losses are massive (-352% margin), and net losses widened to $14.5M. The balance sheet shows negative equity (-$1.85M), and cash flow is deeply negative (-$10.3M operating cash flow), indicating severe liquidity and solvency risks.
Income Statement
12Very NegativeBalance Sheet
5Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.08M | 7.76M | 17.78M | 12.23M | 5.88M | 2.53M |
| Gross Profit | 1.63M | 3.41M | 7.85M | 6.15M | 2.86M | 1.10M |
| EBITDA | -17.74M | -14.55M | -4.06M | -4.27M | -5.10M | -6.70M |
| Net Income | -14.48M | -11.78M | -2.40M | -3.50M | -4.50M | -7.38M |
Balance Sheet | ||||||
| Total Assets | 6.67M | 8.31M | 10.51M | 8.21M | 4.86M | 3.02M |
| Cash, Cash Equivalents and Short-Term Investments | 2.19M | 3.88M | 3.55M | 3.54M | 1.85M | 962.00K |
| Total Debt | 6.39M | 3.51M | 2.55M | 1.70M | 1.47M | 1.13M |
| Total Liabilities | 9.40M | 6.79M | 4.46M | 4.00M | 2.85M | 2.09M |
| Stockholders Equity | -1.85M | 4.04M | 8.85M | 6.84M | 4.88M | 4.65M |
Cash Flow | ||||||
| Free Cash Flow | -10.37M | -8.34M | -4.44M | -2.84M | -3.03M | -3.97M |
| Operating Cash Flow | -10.32M | -8.30M | -3.21M | -2.37M | -2.76M | -3.94M |
| Investing Cash Flow | 51.00K | 435.00K | -1.32M | -478.00K | -271.00K | -34.00K |
| Financing Cash Flow | 8.99M | 8.22M | 4.44M | 4.66M | 3.96M | 4.23M |
BioLargo Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.09, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 20.12 is Positive, neither overbought nor oversold. The STOCH value of -17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.
BioLargo Risk Analysis
BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBioLargo Peers Comparison
Overall Rating
FF53Neutral
RYAM48Neutral
ASIX47Neutral
TROX44Neutral
BLGO38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 53Neutral | $248.71M | -8.10 | -19.75% | 2.47% | -7.63% | -15.10% | |
| 48Neutral | $447.13M | -3.18 | -52.28% | ― | -3.56% | 68.49% | |
| 47Neutral | $414.74M | -23.27 | -2.20% | 4.17% | 2.96% | -122.83% | |
| 44Neutral | $574.92M | -1.04 | -40.45% | 5.56% | 3.53% | -118.53% | |
| 38Underperform | $21.88M | -1.55 | -548.88% | ― | -70.95% | -257.36% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BLGO | BioLargo | 0.07 | -0.09 | -58.86% | |
| FF | Futurefuel | 5.67 | 1.94 | 51.89% | |
| TROX | Tronox | 3.60 | 0.41 | 12.71% | |
| RYAM | Rayonier Advanced Materials | 6.61 | -0.09 | -1.34% | |
| ASIX | AdvanSix | 15.36 | -2.70 | -14.95% |
BioLargo Corporate Events
BioLargo Reports Commercial Traction for ViaCLYR Wound Solution
PositiveOn November 2, 2026, BioLargo said its subsidiary Clyra Medical had gained commercial traction for ViaCLYR, an FDA 510(k)-cleared wound irrigation solution, following the Fall 2026 Symposium on Advanced Wound Care. Since its March 2026 commercial lau...
BioLargo Highlights Investor Presentation and Disclosure Practices
NeutralOn September 10, 2026, BioLargo, Inc. presented a slide deck at a webcast investor conference, and subsequently furnished those materials to the U.S. Securities and Exchange Commission in a Current Report on Form 8-K. The company emphasized that the...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026